1. The Impact of Escitalopram on IL-2-Induced Neuroendocrine, Immune, and Behavioral Changes in Patients with Malignant Melanoma: Preliminary Findings
- Author
-
Daniel S. Graciaa, Lindsay Oliver, Dominique L. Musselman, David H. Lawson, Marcia D. McNutt, Erica B. Royster, Qi Long, Tara K Mann, Lisa M. Trimble, Andrew H. Miller, Ming Wang, and N S Freda Auyeung
- Subjects
Adult ,Male ,medicine.medical_specialty ,Hydrocortisone ,Serotonin reuptake inhibitor ,Antineoplastic Agents ,Adrenocorticotropic hormone ,Citalopram ,Placebo ,Medication Adherence ,Adrenocorticotropic Hormone ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,Escitalopram ,Melanoma ,Aged ,Pharmacology ,Depression ,Interleukin-6 ,Middle Aged ,Antidepressive Agents ,Psychiatry and Mental health ,Treatment Outcome ,Endocrinology ,Concomitant ,Interleukin-2 ,Antidepressant ,Original Article ,Drug Therapy, Combination ,Female ,Psychology ,medicine.drug - Abstract
Interleukin (IL)-2, a T-cell cytokine used to treat malignant melanoma, can induce profound depression. To determine whether pretreatment with the antidepressant escitalopram could reduce IL-2-induced neuroendocrine, immune, and neurobehavioral changes, 20 patients with Stage IV melanoma were randomized to either placebo or the serotonin reuptake inhibitor, escitalopram (ESC) 10–20 mg/day, 2 weeks before, and during IL-2 treatment (720 000 units/kg Q8 h × 5 days (1 cycle) every 3 weeks × 4 cycles). Generalized estimation equations were used to examine HPA axis activity (plasma ACTH and cortisol), immune activation (plasma IL-6), and depressive symptoms (Hamilton Depression Rating Scale (HDRS) score). Tolerance of IL-2 treatment (concomitant medications required) and adherence (number of IL-2 doses received) were also assessed. Both the groups (ESC (n=9), placebo (n=11)) exhibited significant IL-2-induced increases in plasma cortisol, IL-6, and depressive symptoms (p
- Published
- 2013
- Full Text
- View/download PDF